Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06040541 |
Recruitment Status :
Recruiting
First Posted : September 15, 2023
Last Update Posted : February 1, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC) Advanced Solid Tumors | Drug: RMC-9805 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 290 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors |
Actual Study Start Date : | September 7, 2023 |
Estimated Primary Completion Date : | August 30, 2025 |
Estimated Study Completion Date : | July 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: RMC-9805
Dose exploration and dose expansion
|
Drug: RMC-9805
Oral Tablets |
- Adverse events [ Time Frame: Up to 3 years ]Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs
- Dose Limiting Toxicities [ Time Frame: 21 days ]Number of participants with Dose Limiting Toxicities (DLTs)
- Maximum Observed Blood Concentration (Cmax) of RMC-9805 [ Time Frame: up to 21 weeks ]Cmax
- Time to Reach Maximum Blood Concentration (Tmax) of RMC-9805 [ Time Frame: up to 21 weeks ]Tmax
- Area Under Blood Concentration Time Curve (AUC) of RMC-9805 [ Time Frame: up to 21 weeks ]AUC
- Ratio of accumulation of RMC-9805 from a single dose to steady state with repeated dosing [ Time Frame: up to 21 weeks ]accumulation ratio of RMC-9805
- Elimination Half-Life (t1/2) of RMC-9805 [ Time Frame: up to 21 weeks ]t1/2
- Overall Response Rate (ORR) [ Time Frame: up to 3 years ]Assess per RECIST v1.1
- Duration of Response (DOR) [ Time Frame: up to 3 years ]Assess per RECIST v1.1
- Disease Control Rate (DCR) [ Time Frame: up to 3 years ]Assess per RECIST v1.1
- Time to Response (TTR) [ Time Frame: up to 3 years ]Assess per RECIST v1.1
- Progression-Free Survival (PFS) [ Time Frame: up to 3 years ]Assess per RECIST v1.1
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically documented, locally advanced or metastatic solid tumor malignancy with KRASG12D-mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
- ECOG performance status 0 or 1
- Adequate organ function
Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or active brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Participant was previously treated with an investigational KRASG12D inhibitor or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)
Other inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06040541
Contact: Revolution Medicines, Inc. | (650) 779-2300 | CT-inquiries@RevMed.com |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
United States, North Carolina | |
Carolina BioOncology Institute | Recruiting |
Huntersville, North Carolina, United States, 28078 | |
United States, Ohio | |
The Christ Hospital | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
United States, Texas | |
Mary Crowley Cancer Research | Recruiting |
Dallas, Texas, United States, 75230 | |
University of Texas, MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
START | Recruiting |
San Antonio, Texas, United States, 78229 | |
United States, Virginia | |
NEXT Oncology Virginia | Recruiting |
Fairfax, Virginia, United States, 22031 |
Study Director: | Revolution Medicines, Inc. | Revolution Medicines, Inc. |
Responsible Party: | Revolution Medicines, Inc. |
ClinicalTrials.gov Identifier: | NCT06040541 |
Other Study ID Numbers: |
RMC-9805-001 |
First Posted: | September 15, 2023 Key Record Dates |
Last Update Posted: | February 1, 2024 |
Last Verified: | September 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
KRAS G12D (ON) NSCLC CRC PDAC Non-small Cell Lung Cancer Lung Cancer Colorectal Cancer Colon Cancer |
Pancreatic Cancer Metastatic Cancer Pancreatic Ductal Adenocarcinoma Pancreatic Neoplasms Colorectal Neoplasms Gastrointestinal Neoplasms KRAS Colonic Neoplasms |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Adenocarcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |